Oncologia.mx.- Personalized medicine is a global trend that has already arrived in our country and could bring great benefits to the health sector. One of the companies in the field of health that conducts studies on this topic is Roche Mexico, during the World DNA Day, organized a virtual panel called “Rewriting the history of health, one patient at a time”; where Bettina Zimmermann from Roche Farma Internacional, Dr. Carmen Aláez from the National Institute of Genomic Medicine (INMEGEN), Dr. Carlos Sorroza López, Senior Medical Advisor at IQVIA and Mtro. Kenji Lopez of the Cancer Warriors of Mexico, AC
The goal of personalized medicine is to make diagnoses early and with high accuracy, so that each patient obtains appropriate treatment based on the specific origin of the disease, as well as quality monitoring and care. One of the cases in which excellent results have been obtained is in the field of oncology.
In her participation, Betina Zimmermann said that personalized medicine offers the right patient, at the right time, the right treatment. Personalized medicine allows patients to significantly improve their quality of life, “because not all patients are the same and there are several lines of treatment that benefit us.”
While, Mtro. Kenji López Cuevas said it is important for governments to consider the benefits of personalized medicine to better invest the budget, to automate spending. “Consider the benefits in the short and long term, less hospitalization time and recovery of patients,” so he said it is important to disseminate data, real experiences about these treatments.
He added that one of the main challenges is education, “the patient and decision makers must be empowered to have the arguments for why these treatments should be implemented in the health sector in Mexico.”
Dr. Carlos Sorroza López said that 8% of the costs allocated for the treatment of cancer are intended for diagnosis, while 70% are allocated to treatments that often do not benefit patients.
Meanwhile, Dr. Carmen Aláez spoke about the importance of biomarkers, because in regions that are prone to the development of a certain disease, tests are applied from young people to avoid a late diagnosis and to provide appropriate treatment.
He added that patients with Mendelian diseases today can benefit from this type of medication.
The experts agreed that it is the responsibility of all to promote the adoption of new ways of treating diseases, in this regard the importance of empowering patients to participate more actively in decision-making about their health, authorities and institutions of engagement, updating health professionals and contributing private initiative in connection with innovation and the development of new diagnostic and treatment solutions.
In the end, Rachelle Neumann, communications leader for Roche Mexico, stressed: “It is important to show the significance of this issue in the voices of various experts that allow us to provide a complete overview of the current impact and evolution of personalized medicine. approaches are a great opportunity to have more accurate diagnoses and treatments for the benefit of society as a whole ”.
You may be interested in:
Only 28% of patients with AML have a five-year survival rate
CMOM and Pfizer work together to strengthen the knowledge of medical oncologists